title: [3-year results of clinical and immunological monitoring of patients with multiple sclerosis treated by copaxone].
abstract: Tipe 1 T-helper cells are of importance in development of multiple sclerosis (MS). Copaxone (TEVA, Israel) is one of the preventive drugs, which modifies T-helpers activity. Thirty-three patients with MS were treated by copaxone for 2 years and 13 patients--for 3 years. Clinical and immunological parameters were examined: amount of CD3+, CD4+, CD8+, CD16+, CD22+, CD95+, CD25+ lymphocytes, HLA-D+ cells, IgG, IgA, IgM and phagocytosis. During the treatment course, mean rate of relapses decreased from the pretreatment value from 1.26 +/- 0.11 to 0.59 +/- 0.11 in the first year and 0.28 +/- 0.07 in the second one. After 3 years no relapses were observed in 13 patients. Relapse rate was the highest in the first 3-6 months. But after 3 months there was an increase of CD22+ cells that persisted for all the period of the study. After a year of the treatment, a level of IgM, IgG, IgA and CD95+ cells has raised significantly, with decreasing of a number of CD4+ and CD8+ cells. The authors suggest that immunological shift is related to mechanism of copaxone action determining its positive effect i.e. reducing of frequency of MS relapses.
authors.forename: Iu Iu
authors.initials: IuIu
authors.lastname: Orlova
authors.forename: V M
authors.initials: VM
authors.lastname: Alifirova
authors.forename: N V
authors.initials: NV
authors.lastname: Cherdyntseva
authors.forename: I A
authors.initials: IA
authors.lastname: Zagrebina
authors.forename: I V
authors.initials: IV
authors.lastname: Bychkova
mesh_terms: D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000276:immunology*; D002648:Child; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015166:Monitoring, Immunologic; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D010455:Peptides / Q000627:therapeutic use*
chemical_list: D015703:Antigens, CD; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate